All In Biotech

Drug Trial Radar · NCT06072586

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With PK-triggered Expansion Cohort

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

82

Planned (sponsor's estimate)

Start

Oct 18, 2023

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
St. Joseph's Hospital and Medical Center, PhoenixAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ivy Brain Tumor Center; Barrow Neurological Institute
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will administer the investigational drug, BDTX-1535 to eligible patients with recurrent high-grade glioma (HGG) and newly-diagnosed glioblastoma (nGBM). BDTX-1535 was designed to block a growth signal important to some cancers. BDTX-1535 is being tested in this study to see if it can be given safely to people who have tumors that can be dependent on that growth signal because of changes in a protein called EGFR. These gene changes are called amplifications, mutations, fusions or alterations and are found only in the tumors. The study design includes a Phase 0 component with PK/PD-trigger for participant enrollment into an Expansion Phase 1 component. The primary objective of the Phase 0 component is to evaluate the PK endpoints of BDTX-1535. The primary objective of the Phase 1 component is to establish the safe dose of BDTX-1535 to be used in participants with a specified treatment regimen, three of which include standard of care radiotherapy for nGBM participants.

Conditions

  • High Grade Glioma
  • Glioblastoma

Interventions

  • BDTX-1535Drug

    BDTX-1535 is an inhibitor of EGFR mutations

  • BDTX-1535 combined with radiation therapyDrug

    During Phase 1, BDTX-1535 concurrently with standard of care upfront RT, followed by adjuvant monotherapy with BDTX-1535 continuously in 28-day cycles after RT.

  • BDTX-1535 combined with temozolomide and radiation therapyDrug

    During Phase 1, BDTX-1535 concurrently with standard of care upfront RT and TMZ, followed by adjuvant BDTX-1535 combined with standard of care TMZ continuously in 28-day cycles after RT.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Unbound BDTX-1535 Concentration in Tumor TissueTime frame: Intraoperative
  2. Total BDTX-1535 Concentration in Tumor TissueTime frame: Intraoperative
  3. Incidence of DLTs ObservedTime frame: From day of first dose to the end of concurrent RT treatment at 10 weeks
  4. Number of Participants with Treatment-Emergent Adverse Events (TEAEs) as Assessed by NCI-CTCAE v5Time frame: Day of first dose until 30 days after final day of participation
  5. Number of Participants with Treatment-Related Adverse Events (TRAEs) as Assessed by NCI-CTCAE v5Time frame: Day of first dose until 30 days after final day of participation
  6. Number of Participants with Abnormal Laboratory Values as Assessed per NCI-CTCAE v5Time frame: Day of first dose until 30 days after final day of participation

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Chandler Regional Medical Center

    Chandler, Arizona · Recruiting

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.